YIT’s Q4 results and 2026 guidance were well within our expectations.
* Strong FM&WT EBIT margin (19% vs. ABGSCe 15%) * We trim our margin estimates for Decommissioning a...
Redeye comments on Annexin’s Q4 report and recent events and see good initial progress in the phase ...
As we highlighted in our initiation of coverage report, Berner Industrier’s previous financial targe...
Redeye notes that AVTECH's Q4 2025 results aligned with preliminary figures whilst falling short of ...
Redeye provides its initial take on CTEK’s Q4 numbers, where sales were slightly lower than expected...
* Lower earnings due to FX and inventory adjustments * Q4 deviation and FX to negatively impact ABGS...
Berner Industrier continues to impress with a solid 62% y/y improvement in adj.
Redeye comments on Vitec’s Q4 report. While Cash EBIT declined y/y, as expected, organic subscriptio...
Redeye provides its initial take on MedCap’s Q4 2025 report, which came in broadly in line with our ...
Redeye views Gapwaves' Q4 2025 report as modestly positive, with results surpassing estimates on net...
Fiskars' Q4 adjusted EBIT came in below Modular Finance consensus, owing to the Other segment.
Redeye retains its positive view of Transtema. While Q4, as already announced, was weak, we are enco...
* PDUFA action date for Orviglance in July * Cash runway into Q4'26 * Fair value range updated: SEK ...
EQL Pharma redovisade ökad nettoomsättning och EBIT i det tredje kvartalet.
Given that Q4 was broadly in line excluding one-off revenue, our estimate revisions are limited over...
We believe Aktia’s outlook for 2026 was below expectations: the top line looks fine (one could argue...
* NOI -1% and rec PTP -10% vs ABGSCe * Occupancy -0.
Endomines H2 results were fairly in line with expectations, with main deviations relating to one-off...
DT’s Q4 results were largely in line with estimates as revenue declined by 6% y/y while EBITA was do...
